Neurocrine Biosciences Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for NBIX, updated each market day.
NBIX AI Sentiment
AI sees no strong directional signal for Neurocrine Biosciences Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Sector
Exchange
Market Cap
$13,211,846,269
Cap Tier
Employees
2,000
Headquarters
SAN DIEGO, CA
Listed Since
May 23, 1996
Website
NBIX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NBIX Volatility
Neurocrine Biosciences Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
